Search results for ""

De novo VHH design against PD-L1: a 24% hit rate and a nanomolar lead that competes with three approved antibodies

Case report De novo VHH design against PD-L1: a 24% hit rate and a nanomolar lead that competes with three approved antibodies 46 VHH designed and produced from the target structure 24% hit rate, 11 confirmed binders out of 46 10-20…

De novo antibody design against GPVI: three epitope strategies tested in parallel

Case report De novo antibody design against GPVI: three epitope strategies tested in parallel, and 39 binders out of 46 designs 3 published epitopes targeted in parallel 85% hit rate, 39 confirmed binders in ELISA 35 & 40 nM…

Loyalty Reward Page